Search

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Boehringer Ingelheim good 2021 business performance

2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.

Phase II clinical trial weight loss results

Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)

Positive results Diabetic Macular Ischemia treatment

HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment

License deal with A*STAR to develop cancer antibodies

Facts about the INPULSIS™ trials

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

EASi-HF™ Phase III trial in patients with HFpEF

Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.

Survodutide US FDA Breakthrough Therapy phase 3 trials MASH

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers